The Ensign Group Q3 Earnings Call - ENSIGN GROUP INC

Explicit Guidance:

• FY2026 Earnings per Share (EPS): Raised guidance to $7.94–$8.02 per diluted share (previously $7.75–$7.85); represents 21.5% growth over 2025 and 45.1% growth over 2024.
• FY2026 Revenue: Raised lower end of annual guidance to $5.89 billion, maintaining upper end at $5.92 billion.
• Guidance Assumptions: Based on ~59.5 million diluted weighted average shares, 25% tax rate, inclusion of acquisitions closed and expected through Q4 2026, and expected reimbursement rates.
• Dividends: Company has increased the annual dividend for 23 consecutive years; paid $0.065 per share quarterly common stock dividend.
• Capital Efficiency: Lease-adjusted net debt-to-EBITDA ratio maintained at approximately 2.0x despite significant acquisition spending.
• Liquidity: Over $1 billion in combined dry powder (cash + available line of credit capacity).

Business-Segment Outlook:

• Organic Growth: Management expects strong core business performance in Q4 2026, driven by same-store occupancy at 84% and 86% transitioning, with elevated skilled mix expected to sustain.
• Acquisition Performance Timeline: Newer acquired operations (e.g., Florida, Texas turnarounds) are not expected to be accretive immediately; clinical and financial turnaround typically takes one year or more to contribute meaningfully to overall performance.
• Skilled Mix: Same-store skilled mix revenue grew 10.7%; skilled days grew 7.2%. Management expects skilled payer categories (Medicare, managed care) to continue outpacing industry trends due to clinical outcomes.
• Real Estate (Standard Bear): Currently 183 owned properties (146 leased to affiliates, 37 to third parties); 8 new assets added in Q3. Expect ongoing lease-to-own transitions as leases mature (e.g., large public REITs, family-owned portfolios).
• Pipeline: Strong deal flow anticipated for 2027, including portfolios, mid-sized deals, and one-offs; potential to execute 50–60 acquisitions annually.

Market and Competitive Outlook:

• Florida Expansion: Entered Florida market in 2025 with 9 new operations (all lower-occupancy turnarounds). Expectations include initial clinical/financial challenges and a gradual ramp-up as relationships with managed care plans and hospital systems are solidified.
• Competitive Differentiation: High-performing facilities (12% of eligible ops, 40 buildings) recognized under CMS risk-based survey program; 80% of skilled nursing operations rated 4+ stars.
• Market Share Gains: Census growth outpacing industry; attributed to trust generated by superior clinical outcomes (21% above state average in quality measures, 30% better functional improvement for short-stay residents).
• Deal Sourcing: Diverse pipeline from non-profits, REITs, and private owners; noting an increasing trend of acquiring higher-quality physical plant assets that require less capital investment, alongside traditional turnarounds.

Macro / Industry Outlook:

• Demographics: Continued expectation of powerful demographic tailwinds supporting census momentum and long-term growth.
• Regulatory Environment: Florida described as "middle of the road" regarding regulation, though previously a deterrent due to litigation environment; now viewed as stable.
• Labor Market: Florida characterized as having a good labor environment; focus on retaining leadership and training "AITs" (Assistant/Acting-In Training) to mitigate staffing constraints.
• Reimbursement Rates: Guidance assumes continued expectations for reimbursement rates; variations in reimbursement systems noted as a risk factor.
• Seasonality: Q4 expected to be strong historically; Q3 is typically a weaker quarter for skilled mix, implying Q4 should show further strength.

Strategic Initiatives:

• Clinical Model ("One Clinical"): Integration of therapy and nursing as equal partners; continuous refinement of this model to drive outcomes and referral behavior.
• Technology & AI: Rolling out AI for clinical documentation support, coding, compliance, and clinical decision support in real-time; collaboration with EMR providers and internal tool development.
• Leadership Pipeline: Currently ~52 AITs in training (average 52 annually); focus on recruiting and retaining existing high-performing leaders from acquired operations.
• Acquisition Strategy: Maintaining "locally driven underwriting and transition process"; targeting 50–60 acquisitions per year capacity; expanding footprint in Florida, Colorado, and Washington.
• Real Estate Strategy: Active pursuit of lease conversions to ownership as leases mature to unlock value and reduce operational friction.

Risks and Headwinds to Outlook:

• Acquisition Integration: New acquisitions (especially turnarounds) present clinical, financial, and physical plant challenges; financial contribution delayed by 12+ months.
• Operational Risks: Variations in reimbursement systems, state budget delays, and seasonality impacting census and skilled mix.
• Cost Factors: General economy influence, staffing availability, and variations in insurance accruals.
• Litigation Environment: Specifically noted as a historical red flag in Florida (though currently viewed as stable).
• Leadership Constraints: Leadership availability remains a primary constraint on scaling speed.

Management Tone on the Future:

• Confidence Level: Highly confident in 2026 performance and 2027 execution; describes current momentum as "compelling" and "outstanding."
• Strategic Stance: "Discretionary" growth (opportunistic rather than target-driven); emphasizes discipline and smart capital allocation over rigid volume targets.
• Culture as a Moat: Views "culture," "trust," and "clinical outcomes" as the primary drivers of competitive advantage and future growth, rather than just financial engineering.
• Long-term View: Expects long-term upside from current acquisitions; views the "One Clinical" model and CAPLICO culture as foundational for sustainable performance.

Miscellaneous:

• Corporate Structure: Enzyme Group is a holding company with no direct operating assets; operating subsidiaries (Service Center, Insurance Captive, Standard Bear) are independently operated.
• Acquisition Stats: 122 new operations closed/transitioned since 2024; added 22 new operations (2,373 beds) and 3 real estate assets in the current quarter.
• Geographic Focus: Recent additions in Florida, Colorado, Washington, and Texas; 22% of portfolio now in recently acquired group.
• Financial Metrics: Same-store skilled mix revenue +10.7% YoY; Medicare days +7.6% YoY; managed care revenue +9.1% YoY.